With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.
News & Analysis: Alexion Pharmaceuticals
The Nasdaq Composite looked to get back into record territory on Monday.
Alexion finally gets taken out.
These two biotech companies are safe bargains in today's volatile market.
These stocks can bring investors substantial returns for many years to come.
A falling market represents the perfect opportunity to buy into these game-changing companies.
ALXN earnings call for the period ending September 30, 2020.
The biotech delivered strong top- and bottom-line growth and boosted its full-year outlook.
These two rare-disease drug developers are experts at penetrating their markets.
These two companies are well-positioned to deliver market-beating returns for years to come.